KIR2DL1 and neoplasm: A study by He et al. showed that KIR2DL1 is expressed on tumor-infiltrating lymphocytes (TILs) and also on NSCLC cells, and its expression was observed in more NSCLC patients in advanced stages of disease (stages III and IV according to the AJCC) compared to patients with benign stages (stages I and II) [66].